<b>Gapping up <br/>In reaction to strong earnings/guidance:</b> SALE +18.9%, LMNX +11.2%, NLS +11.1%, SANM +10.2%, GEL +8.9%, RNG +8.7%, PERI +7.9%, NPTN +7.2%, TZOO +5.9%, ZTS +5.1%, RTEC +4.9%, AUDC +4.5%, FN +4.2%, INCY +4%, SUP +3.7%, LB +3.4%, MBLY +3.4%, AFSI +3.3%, DISCA +3.1%, TXRH +3%, ONDK +2.7%, UNT +2%, CDE +1.9%, GNC +1.9%, CFMS +1.8%, CFMS +1.8%, SSNC +1.7%, PXD +1.7%, NRZ +1.6%, ALL +1.1%, MOS +1.1%, MCEP +1%<br/><br/><b>M&A news: </b>KING +15.1% (to be acquired by Activision Blizzard (ATVI) for $18 per share ), NGLS +9.9% (to be acquired by Targa Resources (TRGP) in an all-stock transaction at a ratio of 0.62 TRGP shares per NGLS share), AEO +7.5% (acquires Tailgate Clothing Company for ~$11 mln; raises Q3 EPS guidance to ~$0.34), EMC +0.5% (Dell might sell $10 bln in assets to secure EMC deal, according to Reuters)<br/><br/><b>Other news:</b> BKD +15.3% (concluded executive search process; hired Labeed Diab as COO and Lucinda Baier as CFO), ZSAN +10.2% (reported positive results from the Phase 1 clinical trial of ZP-Triptan patch for migraine), ZNGA +5.9% (KING peer), CVM +5.7% (Park West Asset Management disclosed 5.7% passive stake in 13G filing), GLUU +5.2% (KING peer), RGLS +5.2% (Regulus Therapeutics and GlaxoSmithKline (GSK) announce a Phase II study to evaluate the combination of RG-101 and GSK2878175), VRX +4.5% (Philidor to wind-down principal operations), SBBP +4% (reports COR-004 results at the Society for Endocrinology BES 2015 conference; trial met its key efficacy endpoint of IGF-1 level reduction), INCY +4% (reports findings from its Phase 1/2 study of epacadostat), GNC +1.9% (announces it has resumed market share repurchases and will repurchase an additional $200 mln before the end of 2015), MWW +1.4% (CEO disclosed purchase of 25000 shares, worth total of $155.5K; transaction date 10/30), VSR +1.2% (announces the award of two new task orders; combined value is $17.1 mln), P +1.1% (Eminence Capital discloses 5.6% passive stake in 13G filing), ISIS +1% (reports an update on ISIS-TTR Rx, including positive data from multiple clinical studies)<br/><br/><b>Analyst comments:</b> N/A<br/><br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance: </b>VSH -13.1%, AMAG -11.3%, QLYS -11%, NMM -10.4%, AQXP -10.3%, TNET -9.3%, S -8.5%, CGNX -8.4%, CAR -7.7%, EXLP -7.4%, DWRE -7.3%, ADM -7.3%, FIT -7.2%, TASR -6.5%, CGEN -6.2%, UBS -6.1%, AEIS -5.3%, ANIP -5.1%, UNXL -5%, OLN -4.8%, UNVR -4.8%, ODP -4.4%, GGP -3.9%, DBVT -3.6%, ARIA -3.6%, AXLL -3.5%, K -3.3%, AIG -2.9%, AXON -2.8%, NCLH -2.8%, VGR -2.7%, FTR -2.5%, DNOW -2.2%, MDCO -2.2%, ZIOP -2%, AMC -1.8%, OHI -1.5%, EMR -1.4%, KMT -1.3%, KONA -1.2%, TDOC -1%<br/><br/><b>M&A news:</b> EJ -6.1% (receives revised non-binding 'going private' proposal for $6.64/share)<br/><br/><br/><b>Other news</b>: ASC -12% ( announces a 4 mln share secondary offering by selling stockholder, GA Holdings), AQXP -10.3% (reports results from Phase 2 KINSHIP trial with AQX-1125; trial did not meet primary endpoint), AREX -5.4% (to be removed from the S&P SmallCap 600), SUI -3.7% (prices offering of 3,250,000 shares of common stock at $65.00 per share), HTZ -3.3% (following CAR results), FCAU -1.8% (reported October 2015 US sales), GSK -1.4% (Pfizer (PFE) spoke to GSK about M&A deal before talks with Allergan (AGN), according to FT), AEG -0.8% (receives designation as 'systemically important' by the Financial Stability Board)<br/><br/><b>Analyst comments: </b>CNX -3.2% (downgraded to Sell from Hold at Deutsche Bank), MDLY -2.4% (downgraded to Mkt Perform at FBR Capital), NVDA -0.7% (downgraded to Hold at Needham).<br/><br/>Briefing.com